Abstract:Masao Yamaguchi, 1 Yoshihiro Nishimura, 2 Yuko Takumi, 3 Nobuya Hayashi, 4 Kei Sakamoto, 3 Yuji Tohda 5 1 Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan; 2 Kita-Harima Medical Center, Ono, Hyogo, Japan; 3 Patient Safety Division, Research and Development, AstraZeneca K.K., Osaka, Japan; 4 Data Science and Innovation Division, Research and Development, AstraZeneca K.K., Osaka, Japan; 5 Department of Respiratory Medicine and Allergology, Kindai University School of Medicine, Osaka-Sayama, Osaka, Japan Correspondence: Masao Yamaguchi, Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan, Tel +81-436-62-1211, Fax +81-436-62-7340, Email Introduction: This study aimed to demonstrate whether benralizumab maintained the safety and effectiveness profiles established in randomized controlled trials among all patients with severe uncontrolled asthma initially prescribed benralizumab in the real-world setting in Japan. Methods: This was a prospective, observational, multicenter post-marketing study (ClinicalTrial.gov, NCT03588546). The safety and tolerability of benralizumab over 1 year were assessed by the incidence of adverse events (AEs), serious AEs, adverse drug reactions (ADRs), and serious ADRs. Patient background characteristics indicating a more frequent onset of ADRs with benralizumab were explored. The main effectiveness assessment was the change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline. Patients with baseline ACQ-5 scores ≥ 1.5 were defined as having severe uncontrolled asthma. Results: In total, 632 patients were evaluated for safety and 274 for effectiveness; 139 patients were included in the severe uncontrolled asthma subgroup. ADRs were reported in 12.7% and serious AEs in 13.0% of patients. Serious infections occurred in 3.8%, serious hypersensitivity in 0.3%, and malignancy in 0.3% of patients. No helminthic infections occurred. In the effectiveness population, benralizumab improved the mean (standard deviation [95% confidence interval]) ACQ-5 score by − 1.16 (1.40 [− 1.36, − 0.96]) from baseline; forced expiratory volume in 1 second by 0.151 (0.440 [0.09, 0.21]) L; and Mini-Asthma Quality of Life questionnaire score by 1.16 (1.29 [0.94, 1.38]) at the last observation. The annual asthma exacerbation rate was 0.42. A greater ACQ-5 score improvement was observed among patients with eosinophilic asthma characteristics. Conclusion: No new safety concerns were raised, and patients experienced benefits consistent with previous studies of benralizumab, thus supporting the use of benralizumab for the add-on maintenance treatment of patients with eosinophilic severe uncontrolled asthma. Keywords: benralizumab, severe uncontrolled asthma, anti-interleukin-5 receptor α monoclonal antibody, eosinophils, exacerbation, asthma control, quality of life In 2019, it was estimated that over 260 million people globally were affected by asthma. 1 Of the total population with asthma, approximately 3%–10% of patients have severe disease and have symptoms and exacerbations despite treatment with maximal standard-of-care controller therapy. 2 The recent KEIFU study, a non-interventional insurance claims database analysis in Japan, reported that 7.8% of continuously treated asthma patients had severe asthma, of whom 2.5% had severe uncontrolled asthma. 3 Patients with severe asthma have a disproportionately high disease burden, reflected by the marked impairment in quality of life and the increased healthcare and societal costs. 4,5 This is also the case in Japan, as reported in a recent analysis of asthma-associated healthcare resource utilization using data from the Japan Medical Data Center database. 6 The analysis showed that healthcare resource utilization was heavily concentrated among severe asthma patients, with significantly more all-cause hospitalizations, outpatient visits, prescriptions, and total medical costs than those with non-severe asthma. 6 Eosinophilic asthma is the most common subtype of severe asthma, accounting for over 80% of cases. 7 An increased number of airway and circulating eosinophils is associated with an increased frequency of asthma exacerbations, a high symptom burden, and impaired lung function. 8–10 Benralizumab (Fasenra ® ) is a humanized, afucosylated, anti-interleukin (IL) 5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils 11 via enhanced antibody-dependent cell-mediated -Abstract Truncated-

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System

Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

A Descriptive Analysis from the Spanish Pharmacovigilance Database

Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study

Update on new biologics for intractable eosinophilic asthma: impact of reslizumab

A Real-World Disproportionality Analysis of Tirzepatide-Related Adverse Events Based on the FDA Adverse Event Reporting System (FAERS) Database

Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Baricitinib.

Postmarketing Analysis of Eosinophilic Adverse Reactions in the use of Biologic Therapies for Type 2 Inflammatory Conditions

Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database

A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib